The molecular pattern of histopathological progression to anaplastic meningioma – A case report

Neurologia i Neurochirurgia Polska

Volumn 50, Issue 4, 2016, Pages 288-293

  Och, Waldemar ^a   Kulbacki, Kamil ^a   Szostak, Błażej ^a   Sikorska, Beata ^b   Zakrzewska, Magdalena ^b   Szmuda, Tomasz ^c   Liberski, Paweł P ^b   Budzisz, Tomasz ^a  

^a Regional Specialistic Pediatric Hospital   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Anaplastic meningioma; Loss of heterozygosity; Meningioma; Molecular biology; Tumour progression

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; HISTONE H3; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADJUVANT RADIOTHERAPY; ADULT; ANAPLASTIC MENINGIOMA; ARTICLE; BRAIN EDEMA; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME 10; CHROMOSOME 14; CHROMOSOME 1P; CHROMOSOME 22; CHROMOSOME 9; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; HEADACHE; HEMIPARESIS; HETEROZYGOSITY LOSS; HISTONE PHOSPHORYLATION; HISTOPATHOLOGY; HUMAN; MALE; MALIGNANT TRANSFORMATION; MENINGIOMA; MICROSATELLITE MARKER; MIDDLE AGED; NEUROIMAGING; SECOND LOOK SURGERY; SUPERIOR SAGITTAL SINUS; TUMOR GROWTH; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME; BRAIN; DIAGNOSTIC IMAGING; DISEASE COURSE; GENETICS; METABOLISM; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

BRAIN; DISEASE PROGRESSION; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84964389460     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.1016/j.pjnns.2016.03.008     Document Type: Article

References (30)

1. [1] Ostrom, Q.T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16:Suppl. 4 (2014), 1–63.
2. [2] Mawrin, C., Perry, A., Pathological classification and molecular genetics of meningiomas. J Neurooncol 99 (2010), 379–391.
3. [3] Fuller, C.E., Perry, A., Molecular diagnostics in central nervous system tumors. Adv Anat Pathol 12 (2005), 180–194.
4. [4] Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 (2007), 97–109.
5. [5] Och, W., Mariak, Z., Kopec, J., Smolka, M., Koziorowski, M., Correlation of expression of progesterone receptors with histopathological type and grade of malignancy of cerebral neoplasms. Neurol Neurochir Pol 35:Suppl. 5 (2001), 110–118.
6. [6] Grunberg, S.M., Weiss, M.H., Russell, C.A., Spitz, I.M., Ahmadi, J., Sadun, A., et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24 (2006), 727–733.
7. [7] Nakasu, S., Fukami, T., Jito, J., Nozaki, K., Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol 26 (2009), 69–72.
8. [8] Choy, W., Kim, W., Nagasawa, D., Stramotas, S., Yew, A., Gopen, Q., et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus, 30, 2011, E6.
9. [9] Simpson, D., The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20 (1957), 22–39.
10. [10] Kleihues, P., Louis, D.N., Scheithauer, B.W., Rorke, L.B., Reifenberger, G., Burger, P.C., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61 (2002), 215–225.
11. [11] Guan, Y., Hata, N., Kuga, D., Yoshimoto, K., Mizoguchi, M., Shono, T., et al. Narrowing of the regions of allelic losses of chromosome 1p36 in meningioma tissues by an improved SSCP analysis. Int J Cancer 122 (2007), 1820–1826.
12. [12] Kalala, J.-P., Caemaert, J., De Ridder, L., Primary resected meningiomas: relapses and proliferation markers. In Vivo 18 (2004), 411–416.
13. [13] Modha, A., Gutin, P.H., Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57 (2005), 538–550.
14. [14] Pfisterer, W.K., Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro Oncol 6 (2004), 290–299.
15. [15] Ohgaki, H., Kleihues, P., Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100 (2009), 2235–2241.
16. [16] Carvalho, L.H., Smirnov, I., Baia, G.S., Modrusan, Z., Smith, J.S., Jun, P., et al. Molecular signatures define two main classes of meningiomas. Mol Cancer, 6, 2007, 64.
17. [17] Riemenschneider, M.J., Perry, A., Reifenberger, G., Histological classification and molecular genetics of meningiomas. Lancet Neurol 5 (2006), 1045–1054.
18. [18] Perry, A., Banerjee, R., Lohse, C.M., Kleinschmidt-DeMasters, B.K., Scheithauer, B.W., A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12 (2002), 183–190.
19. [19] Bagchi, A., Papazoglu, C., Wu, Y., Capurso, D., Brodt, M., Francis, D., et al. CHD5 is a tumor suppressor at human 1p36. Cell 128 (2007), 459–475.
20. [20] Zhang, X., Gejman, R., Mahta, A., Zhong, Y., Rice, K.A., Zhou, Y., et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 70 (2010), 2350–2358.
21. [21] Lusis, E.A., Watson, M.A., Chicoine, M.R., Lyman, M., Roerig, P., Reifenberger, G., et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65 (2005), 7121–7126.
22. [22] Mihaila, D., Jankowski, M., Gutiérrez, J.A., Rosenblum, M.L., Newsham, I.F., Bögler, O., et al. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clin Cancer Res 9 (2003), 4443–4451.
23. [23] Sinkre, P., Perry, A., Cai, D., Raghavan, R., Watson, M., Wilson, K., et al. Deletion of the NF2 region in both meningioma and juxtaposed meningioangiomatosis: case report supporting a neoplastic relationship. Pediatr Dev Pathol 4 (2001), 568–572.
24. [24] Wozniak, K., Piaskowski, S., Gresner, S.M., Golanska, E., Bieniek, E., Bigoszewska, K., et al. BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. Cancer Genet Cytogenet 183 (2008), 14–20.
25. [25] Barski, D., Wolter, M., Reifenberger, G., Riemenschneider, M.J., Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 20 (2010), 623–631.
26. [26] Stawski, R., Piaskowski, S., Stoczynska-Fidelus, E., Wozniak, K., Bienkowski, M., Zakrzewska, M., et al. Reduced expression of ELAVL4 in male meningioma patients. Brain Tumor Pathol 30 (2013), 160–166.
27. [27] Goutagny, S., Yang, H.W., Zucman-Rossi, J., Chan, J., Dreyfuss, J.M., Park, P.J., et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 16 (2010), 4155–4164.
28. [28] Linsler, S., Kraemer, D., Driess, C., Oertel, J., Kammers, K., Rahnenführer, J., et al. Molecular biological determinations of meningioma progression and recurrence. PLOS ONE, 9, 2014, e94987.
29. [29] Al-Mefty, O., Kadri, P.A.S., Pravdenkova, S., Sawyer, J.R., Stangeby, C., Husain, M., Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101 (2004), 210–218.
30. [30] Krayenbuhl, N., Pravdenkova, S., Al-Mefty, O., De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome. Neurosurgery 61 (2007), 494–495.